meta
|
evidence
oncology
Living systematic review and meta-analysis
NSCLC neoadjuvant setting
1
lung cancer : small cell (SCLC)
chemotherapy
non platinum-based chemotherapy
alkylating agents
lurbinectedin
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
durvalumab based treatment
durvalumab plus etoposide and platin
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab plus SoC
anti-TIGIT
tiragolumab
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC
nivolumab plus ipilimumab
no study with result for this clinical condition